<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322826</url>
  </required_header>
  <id_info>
    <org_study_id>SHDC12015116</org_study_id>
    <nct_id>NCT03322826</nct_id>
  </id_info>
  <brief_title>Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity</brief_title>
  <official_title>A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of systematic sampling of lymph nodes vs.
      lymphadenectomy on outcome according to intraoperative frozen pathology for pulmonary
      invasive adenocarcinoma with ground-glass opacity (GGO) after VATS lobectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On HRCT screening, early lung adenocarcinoma often contains a nonsolid component called
      ground-glass opacity (GGO). In 2011, pulmonary adenocarcinomas were classified into atypical
      adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive carcinoma
      (MIA) and more extensively invasive adenocarcinoma (IAC) [1]. Early adenocarcinomas with
      GGO-dominant always mean low-grade malignancy and have an extremely favorable prognosis
      [2-5]. Previous studies have shown that patients with AAH, AIS and MIA have excellent
      survival rates (5-year survival rate is approximate 95%) after resection, and only 0.83% -
      2.91% patients have lymph node metastasis [6-9]. At present, lymphadenectomy is always
      undergone in patients with pulmonary adenocarcinoma with ground-glass opacity. However, for
      MIA patients (especially in T1a-b stage), the appropriate use of lymphadenectomy continues to
      be debated.

      Nowadays, intraoperative frozen pathology is widely used during operation. However, whether
      sampling of lymph nodes or lymphadenectomy should be performed for GGO lesions according to
      intraoperative pathological diagnosis is unclear. The aim of this prospective study is to
      evaluate whether there are any trends regarding the impact of subtypes of invasive
      adenocarcinoma according to intraoperative frozen pathology in sampling of lymph nodes vs.
      lymphadenectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">October 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>five years after surgery</time_frame>
    <description>recurrence-free survival status of patients after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>five years after surgery</time_frame>
    <description>survival status of patients after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>the rates of complications related to treatment during perioperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>the rates of death related to treatment during perioperative period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Lymph Node Excision</condition>
  <arm_group>
    <arm_group_label>Lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>systematic sampling of the lymph nodes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>systematic sampling of the lymph-node</intervention_name>
    <description>Systematic Sampling of lymph nodes</description>
    <arm_group_label>systematic sampling of the lymph nodes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphadenectomy</intervention_name>
    <description>Routine lymph nodes dissection in lung cancer</description>
    <arm_group_label>Lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A peripheral nodular lesion;

          2. The maximum diameters of whole GGO lesions and solid components on lung windows were
             no more than 3 cm (T1 stage);

          3. VATS lobectomy

          4. 25%≦Consolidation/Tumor ratio ≦50%

          5. ECOG performance status 0-2;

          6. Without distant metastasis;

          7. Intraoperative frozen pathology confirmed invasive or minimally invasive
             adenocarcinoma.

          8. No operation contraindication

          9. Cardiovascular: Cardiac function normal

         10. Renal: Creatinine clearance greater than 60 ml/min

         11. The expected survival after surgery ≥ 6 months

         12. Must be able to sign written informed consent form

        Exclusion Criteria:

          1. Age less than 18 years old

          2. Known hereditary bleeding disorder with history of post-operative hemorrhage

          3. Patients maintained on chronic anticoagulation (eg Coumadin therapy)

          4. Known hematogenous disorder

          5. Known primary or secondary malignancy

          6. Pregnant or breast-feeding women;

          7. Clinically significant heart disease;

          8. Patients who are unwilling or unable to comply with study procedures;

          9. Receiving immunosuppressive therapy;

         10. HIV/AIDS.

         11. Multiple lesions in lung
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang Chen, M.D. Ph.D.</last_name>
    <phone>13816869003</phone>
    <email>chenthoracic@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Chen, MD,PhD</last_name>
      <phone>13816869003</phone>
      <email>chenthoracic@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014 Jan;145(1):66-71. doi: 10.1378/chest.13-1094.</citation>
    <PMID>24551879</PMID>
  </results_reference>
  <results_reference>
    <citation>Ye B, Cheng M, Li W, Ge XX, Geng JF, Feng J, Yang Y, Hu DZ. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014 Jul;98(1):217-23. doi: 10.1016/j.athoracsur.2014.03.005. Epub 2014 May 17.</citation>
    <PMID>24841547</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Chang Chen</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

